eslicarbazepine / Generic mfg. - LARVOL DELTA

Pharmacological characterization of the harmaline mouse model of essential tremor using integrated multimodal biomarker profiling (Neuroscience 2026) - "Across multiple cohorts, we evaluated nine mechanistically distinct compounds: agents used clinically in ET management (propranolol, gabapentin, alprazolam), selective T-type calcium channel inhibitors in clinical development (ulixacaltamide, suvecaltamide), and pharmacological probes targeting ET-relevant pathways (eslicarbazepine, ethanol, caffeine, ganaxolone). T-type calcium channel inhibitors produced the most robust peripheral tremor suppression, with ulixacaltamide and suvecaltamide displaying a distinctive biphasic coherence response that distinguished their mechanistic profile from other compounds.Together, these findings demonstrate that integrated central and peripheral biomarker profiling reveals mechanism-specific pharmacological signatures not captured by single-endpoint approaches. This work establishes a pharmacological reference dataset and translational framework for preclinical drug evaluation in ET."

Preclinical • CNS Disorders • Essential Tremor • Movement Disorders

Anti Tremorgenic Properties Of Eslicarbazepine Acetate in The Harmaline Induced Tremor Mouse Model (MDS Congress 2026) - No abstract available

Preclinical • CNS Disorders • Movement Disorders

Time-dependent retention and discontinuation of eslicarbazepine acetate treatment in real-world focal epilepsy: The first three months as a key period. (PubMed, Clin Neurol Neurosurg) - "The first 3 months are a key period for optimizing treatment retention and minimizing adverse events. Careful consideration of concomitant ASM is required, as concomitant ASM may be associated with lower retention and more adverse events, particularly sodium channel blockers."

Journal • Real-world evidence • CNS Disorders • Epilepsy

Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents. (PubMed, CNS Drugs) - "Overall, newer-generation ASMs, including rufinamide, lacosamide, brivaracetam, cannabidiol, fenfluramine, and ganaxolone, demonstrate generally favourable cognitive profiles when used at recommended doses, particularly in monotherapy or rational polytherapy. Eslicarbazepine and cenobamate may be associated with mild, dose-dependent cognitive effects, occurring only at the upper end of the recommended dose range. In contrast, old ASMs and certain second-generation agents, notably topiramate and zonisamide, remain consistently associated with higher cognitive risks...Cognitive dysfunction in epilepsy is multifactorial, reflecting the interaction between disease-related neurobiological mechanisms and treatment effects. Optimal management requires balancing seizure control with cognitive preservation through individualised drug selection, cautious titration, and minimisation of polytherapy to achieve the best functional and quality-of-life outcomes."

Adverse events • Journal • Review • CNS Disorders • Cognitive Disorders • Developmental Disorders • Epilepsy • Mental Retardation

Narrative Review: Efficacy, Safety, and Tolerability of Newer Third-Generation Antiseizure Medications for Focal Epilepsy: A New Benchmark in Treatment Outcomes? (PubMed, Neurol Ther) - "All third-generation ASMs were effective adjunctive therapies. Cenobamate was associated with higher responder and seizure freedom rates and higher long-term retention rates. Brivaracetam and lacosamide had favorable tolerability profiles. The notable seizure freedom rates with cenobamate suggest a potential new benchmark in focal seizure treatment. Comparator trials are needed to confirm possible efficacy and tolerability differences among third-generation ASMs."

Journal • Review • CNS Disorders • Eosinophilia • Epilepsy • Fatigue • Pain • Psychiatry

ENGAGE: Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures (clinicaltrials.gov) - P=N/A | N=1500 | Recruiting | Sponsor: King Edward Medical University

HEOR • New trial • Real-world evidence • CNS Disorders • Epilepsy

Advances in Sodium Channel Modulation in Epilepsy Therapy: Focus on Eslicarbazepine, Lacosamide and Cenobamate. (PubMed, Biomedicines) - " Recent advances in sodium channel modulation have expanded therapeutic options for focal epilepsy and support the development of more selective, mechanism-based ASM therapies. Eslicarbazepine acetate, lacosamide, and cenobamate demonstrate favorable efficacy and tolerability profiles and may improve seizure control in patients with drug-resistant epilepsy."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy • Fatigue • Heart Failure

Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment. (PubMed, Clin Pharmacokinet) - "Ten newer antiseizure medications (ASMs) approved since 2000 and selected for this review (cenobamate, brivaracetam, eslicarbazepine acetate, lacosamide, perampanel, fenfluramine, ganaxolone, cannabidiol, stiripentol, and rufinamide) have broadened treatment options for drug-resistant epilepsy. Regulatory discrepancies between FDA and EMA labeling were identified for all ten agents, notably divergent hepatic dose caps for perampanel and cenobamate, conflicting renal recommendations for fenfluramine, and discordant guidance for eslicarbazepine acetate in severe renal impairment. These agents exhibit no uniform class effect in organ impairment; prescribing must be governed by agent-specific disposition profiles, organ-function severity, and free-drug monitoring for highly protein-bound agents like perampanel and ganaxolone."

Journal • PK/PD data • Review • CNS Disorders • Epilepsy • Hepatology • Nephrology • Renal Disease

Acute effects of anti-seizure medications on network level dynamics: A systematic comparison using multielectrode arrays. (PubMed, Epilepsia) - "Several limitations should be considered, including the use of primary neuron cultures, incomplete maturation of certain drug targets, evaluation of only acute drug effects, and the limited spatial resolution of low-density MEA systems. Nevertheless, our results demonstrate that this MEA-based platform enables systematic evaluation of ASM effects on neuronal networks under identical experimental conditions. Furthermore, multivariate and unsupervised clustering analysis of 44 MEA parameters facilitated classification independent of drug mechanism of action. These findings suggest that MEA, combined with multidimensional data analysis, may provide a useful platform for the direct comparison of ASMs and could contribute to future pharmacological screening and drug discovery efforts."

Journal • CNS Disorders • Epilepsy

Anti-seizure medication in Germany over 25 years: trends in prices and prescription patterns from national data from 2000 to 2024. (PubMed, Epilepsy Behav) - "The observed prescription shifts align well with the recommendations of German clinical practice guidelines, which advocate preferential use of lamotrigine and levetiracetam and lacosamide as first-line agents in focal epilepsies, whilst discouraging the use of enzyme-inducing ASMs due to their unfavourable pharmacokinetic interaction profiles and long-term tolerability concerns. The sustained stability of total ASM expenditure indicates that the German pharmaceutical regulatory framework seems to have contributed effectively to contain ASM expenditures whilst maintaining access to therapeutic innovations."

Journal • CNS Disorders • Epilepsy

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis. (PubMed, Br J Clin Pharmacol) - "Significant signals of DRESS associated with 13 ASMs were identified in paediatric populations. Notably, signals were detected for the first time for ethosuximide, perampanel, fosphenytoin and eslicarbazepine by disproportionality analysis. TTO analysis demonstrated wear-out or random failure-type patterns in the occurrence of ASM-associated DRESS."

Journal • CNS Disorders • Eosinophilia • Epilepsy • Pediatrics

Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis. (PubMed, Seizure) - "Switching from OXC to ESL may represent a pragmatic strategy for patients with OXC-related intolerance, particularly when treatment retention and tolerability are prioritized. However, the observational nature of the available evidence, together with substantial heterogeneity and wide confidence intervals, limits the precision and generalizability of pooled estimates."

Journal • Retrospective data • Review • CNS Disorders • Epilepsy

Eslicarbazepine acetate shows anti-tremorgenic properties in the mouse harmaline-induced tremor model (EAN 2026) - "Animals received ESL (75 and 150 mg/kg, gavage), propranolol (10–20 mg/kg, intraperitoneally) as reference, or vehicle-control, 20–30 min before harmaline (20mg/kg, intraperitoneally). ESL reversed harmaline-induced EEG alterations and attenuated tremor in a mouse model of ET. This effect, possibly attributed to a T-type calcium channel inhibition, suggests a therapeutic potential for this movement disorder."

Preclinical • Epilepsy • Essential Tremor • Movement Disorders

Real-Life Experience of Switching from Branded to Generic Eslicarbazepine Acetate (EAN 2026) - No abstract available

Clinical

Psychiatric Adverse-Event Monitoring in Epilepsy: Lesson from a Systematic Literature Review of Eslicarbazepine Acetate, Lacosamide, and Levetiracetam (EAN 2026) - No abstract available

Adverse events • Review • CNS Disorders • Epilepsy • Psychiatry

Eslicarbazepine acetate exposure in pregnant women with epilepsy: from clinical development to 16 years post-marketing experience (EAN 2026) - No abstract available

Clinical • P4 data • CNS Disorders • Epilepsy

Multimodal Imaging in the Presurgical Evaluation of Epilepsy - An Educative Case Report (OHBM 2026) - "The epilepsy proved resistant to multiple antiseizure medications, including oxcarbazepine, valproate, zonisamide, levetiracetam, lamotrigine, carbamazepine, eslicarbazepine, and phenytoin. From a neuroimaging perspective, this case illustrates how advanced data integration and visualization strategies can translate complex multimodal information into actionable surgical guidance. Beyond seizure freedom, timely and precise intervention may allow recovery of neurodevelopmental trajectories and long-term functional outcomes."

Case report • Clinical • CNS Disorders • Epilepsy

Severe Cutaneous Adverse Reactions Associated With Newer-Generation Antiseizure Medications: A Real-World Pharmacovigilance Study Based on FAERS and JADER. (PubMed, CNS Neurosci Ther) - "Across FAERS and JADER, reporting associations between newer-generation ASMs and SCARs were highly concentrated in a limited set of agents and exhibited phenotype-specific latency patterns. After accounting for polytherapy confounding, levetiracetam and eslicarbazepine emerged as the most consistent under-recognized signals, warranting heightened vigilance during initiation-particularly when co-administered with aromatic ASMs. Drug-phenotype combinations with both high disproportionality and a high reported fatality proportion (notably lamotrigine-TEN and zonisamide-TEN) warrant intensified early monitoring for SJS/TEN and sustained vigilance into maintenance therapy for DRESS, although population-level absolute risk cannot be inferred from spontaneous-report data."

Adverse events • Journal • Real-world evidence • CNS Disorders • Eosinophilia • Epilepsy • Immunology • Steven-Johnson Syndrome

Pregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy: A global safety database analysis from clinical development to 16 years of post-marketing experience. (PubMed, Seizure) - "Across all years with ESL exposure, no consistent pattern of congenital disorders or miscarriages was observed in pregnant women with epilepsy. While large safety databases support signal detection, there remains a need for high‑quality, adequately powered observational studies and continued pharmacovigilance to guide informed clinical decision‑making in this vulnerable population."

Journal • P4 data • CNS Disorders • Epilepsy

Prophylactic Antiepileptic Drugs in Nontraumatic Intracerebral Hemorrhage: A Network Meta-Analysis. (PubMed, Neurocrit Care) - "This NMA found no robust evidence to support the routine prophylactic use of AEDs after nontraumatic ICH. Nonetheless, valproate consistently demonstrated the best efficacy and relative safety profiles. This finding warrants investigation in future RCTs, particularly in subgroups of patients at high risk for post-ICH seizures."

Journal • Retrospective data • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders

Hyponatremia Due to Vasopressin-Independent Antidiuresis Caused by Oxcarbazepine But Not Eslicarbazepine and Corrected with Tolvaptan (NKF-SCM 2026) - "METHODS/CASE SUMMARY 35-year-old woman with seizure disorder on cenobamate and eslicarbazepine acetate chronically presented to an outside facility with suicidal ideation. There, the medication regimen was switched to oxcarbazepine and quetiapine due to the facility's formulary restrictions...CONCLUSION Oxcarbazepine can cause AVP-independent SIAD responsive to tolvaptan. Individual risk for hyponatremia needs to be taken into account when replacing/interchanging antiepileptics."

Cardiovascular • CNS Disorders • Epilepsy • Heart Failure • Nephrology • Suicidal Ideation

Depressive Symptom Changes Following Antiseizure Medication (ASM) Use – A Quantitative Analysis of Clinical Studies (AAN 2026) - "Most anti-seizure medications were correlated with symptoms improvement, with the greatest effects observed for Perampanel (d = –0.77), Brivaracetam (d = –0.55), Lacosamide (d = –0.46), and Eslicarbazepine Acetate (d = –0.41). Conclusions Decreases in depressive symptoms appear to be an underrecognized yet clinically meaningful secondary effect of antiseizure medications. These findings highlight specific medications that may provide the greatest benefit in co-morbid neuropsychiatric symptoms and underscore an importance of integrating psychiatric outcomes into epilepsy treatment decisions."

Clinical • CNS Disorders • Depression • Epilepsy

Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications (AAN 2026) - "Design/Methods De-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated therapeutic doses of cenobamate or another selected ASM (brivaracetam, clobazam, lacosamide, eslicarbazepine, or perampanel) between 1/1/2020-12/5/2024. Similar findings were observed after propensity matching. Conclusions Patients treated with cenobamate at therapeutic doses had lower mortality rates than patients treated with selected comparable ASM."

CNS Disorders • Epilepsy

Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate (AAN 2026) - "Objective To evaluate the comparative effect of initiating cenobamate vs selected antiseizure medications (ASMs, brivaracetam, clobazam, eslicarbazepine, lacosamide, or perampanel) on epilepsy-related and all-cause inpatient (IP) and emergency room (ER) utilization rates. In the all-cause analysis, treatment with cenobamate was associated with a 37% reduction (95% CI: 25%-48%) vs the select ASM group in annual IP admissions, and a 34% reduction (95% CI: 23%-43%) in annual ER visits. Conclusions Initiating cenobamate was associated with a significant reduction in both epilepsy-related and all-cause IP admissions and ER visits compared to propensity-matched patients who similarly could have initiated cenobamate but instead initiated other ASMs."

HEOR • CNS Disorders • Epilepsy

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). (PubMed, Br J Clin Pharmacol) - "This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk-benefit profile, ensuring that therapy is optimised to maximise benefits whilst minimising potential harms."

Biomarker • Journal • Bipolar Disorder • CNS Disorders • Dermatology • Epilepsy • Immunology • Mood Disorders • Neuralgia • Pain • Psychiatry • HLA-B